An Invitation to Participate in EPHAR 2008 On behalf of our colleagues in EPHAR and the British Arthur Weston Pharmacological Society, who are hosting this event, it is our President, Federation of great pleasure to extend a personal invitation to participate European Pharmacological in EPHAR 2008, which will be held in Manchester from 13th to Societies 17th July 2008. Over the 4-day meeting, basic and clinical pharmacologists, together with related bioscientists from EPHAR’s 24 affi liated Pharmacological Societies with a total of 12,000 members, will enjoy an unrivalled scientifi c feast. The programme itself is unparalleled; free scientifi c communications together with plenary lectures and cutting-edge symposia with subject- leading speakers will ensure that EPHAR 2008 is the most important international pharmacological event of the year. EPHAR 2008 will take place at University Place, Manchester University’s brand new International Conference Centre with superb facilities for exhibitors and delegates alike. Set in the heart of the UK’s largest single-site University, with an income of £514 million and 10,400 staff, no organisation whose business encompasses the broad range of products and services used by today’s pharmacologists can afford to miss Jeffrey Aronson out on a unique opportunity to establish important new President, British contacts and consolidate existing ones. Pharmacological Society Manchester itself is easily reached by road, rail or air. Steeped in the history of the Industrial Revolution, the city offers vibrant cultural, leisure and sporting facilities for evening entertainment. The Congress Dinner, to which all participants are warmly invited, will be held at Old Trafford, home of the world-famous Manchester United Football Club. We look forward to seeing you at EPHAR 2008 in Manchester between 13th and17th July; don’t miss the opportunity to be part of this unique event! Arthur Weston President, Federation of European Pharmacological Societies Jeffrey Aronson President, British Pharmacological Society KEY DATES Abstract Submission deadline 20th March 2008 Bursary Application deadline 20th March 2008 Early Bird Registration deadline 20th March 2008 Online Registration deadline 7th July 2008 Dates of Congress 13th -17th July 2008 CONTENTS LIST Committees p. 1 - 3 Scientifi c Programme p. 4 - 14 Satellite Meetings p. 15 - 17 General Information p. 17 - 21 COMMITTEES EPHAR 2008 Executive Committee Chair: Jeffrey Aronson (Oxford), President, British Pharmacological Society (BPS) Arthur Weston (Manchester) President, EPHAR Richard Green (Nottingham) BPS representative on EPHAR Council Mandy MacLean (Glasgow) Vice-President (Meetings), BPS Manfred Göthert (Bonn) Past-President, EPHAR Alan Cuthbert (Cambridge) Past-President, EPHAR Eeva Moilanen (Tampere) EPHAR Executive Committee Daniel McQueen (Edinburgh) Honorary Treasurer, BPS Kate Baillie BPS Chief Executive Kevin Kearns BPS Deputy Chief Executive & Secretary Luisa Hambley BPS Meetings Manager EPHAR 2008 Organising Committee Chair: Mandy MacLean (Glasgow) Committee Members: Kate Baillie (BPS) Susan Brain (London) Mike Curtis (London) Mark Dowling (Novartis) Luisa Hambley (BPS) 1 Kevin Kearns (BPS) Sarah Mackay (BPS) Ian McFadzean (London) Donald Singer (Warwick) Sergey Smirnov (Bath) Domenico Spina (London) Andrew Tobin (Leicester) David Williams (Aberdeen) EPHAR 2008 Scientifi c Advisory Committee Pavel Anzenbacher (Olomouc) Stefan Boehm (Vienna) Ernst Brodin (Stockholm) Marija Čarman-Kržan (Ljubljana) Flaminio Cattabeni (Milan) Oguz Guc (Ankara) George Karakiulakis (Thessaloniki) D A Kharkevich (Moscow) Wojciech Kostowski (Poland) Romain Lefebvre (Ghent) Finn Olav Levy (Oslo) Eeva Moilanen (Tampere) Nela Pivac (Zagreb) Radomir Radomirov (Sofi a) Joaquin-Alexandre Ribeiro (Lisbon) Felipe Sanchez de la Cuesta (Malaga) Jean Sassard (Lyon) 2 Karsten Schrör (Dusseldorf) S B Seredenin (Moscow) Ulf Simonsen (Aarhus) Olivier Staub (Lausanne) Pavel Svec (Bratislava) Janos Szolcsanyi (Pècs) Arthur Weston (Manchester) Hans Zaagsma (Gröningen) 3 SUNDAY CONGRESS MONDAY TUESDAY WEDNESDAY THURSDAY FRIDAY SATURDAY SUNDAY 13 JULY TIMINGS 14 JULY 15 JULY 16 JULY 17 JULY 18 JULY 19 JULY 20 JULY 8.30 - 9.30 Plenary Plenary Plenary Plenary Cardiovascular Cardiovascular Serotonin Club lecture lecture lecture lecture Workshop Workshop Satellite Meeting (Manchester) (Manchester) (Oxford) 9.30 – 12.30 5 x parallel 5 x parallel 5 x parallel 5 x parallel Coffee 10.30- symposia symposia symposia symposia 11.00 Serotonin Club Serotonin Club Satellite Satellite 12.30 – 14.30 Lunch & Lunch & Lunch & Lunch & Meeting Meeting poster viewing poster viewing poster viewing poster viewing (Oxford) (Oxford) 14.30 - 15.30 Oral Oral Oral Oral communications communications communications communications 17.00 15.30 – 16.00 Coffee Coffee Coffee Coffee Open Registration 18.00–18.30 16.00 – 17.00 Oral Oral Oral Oral Welcome communications communications communications communications address 18.30 – 20.00 Evening Informal Social EPHAR Council Congress Dinner Serotonin Club Welcome Events at Old Trafford Satellite Meeting Reception Dinner Oxford 4 SCIENTIFIC PRELIMINARY SCIENTIFIC PROGRAMME PROGRAMME PLENARY LECTURES EPHAR 2008 Lecture Understanding molecular mechanisms and cell injury and death: a way to improve drug safety and design Professor Pierluigi Nicotera, MRC Toxicology Unit, University of Leicester, UK EPHAR President’s Lecture Calcium signalling in health and disease Professor Sir Michael Berridge, The Babraham Institute, UK The AstraZeneca Lecture Advanced medicines: must we exclude the global poor? Professor Thomas Pogge, Yale University, USA and CAPPE, Australian National University, Australia The MSD Lecture New therapeutic targets for asthma and COPD Professor Frans P. Nijikamp, Utrecht University, The Netherlands SYMPOSIA Nitric Oxide-Oxidative and Nitrosative Stresses-PARP Pathway The French NO Society Symposium Organiser: Prof. Catherine Marchand-Leroux, University Paris 5, France Speakers: Nitric Oxide, Nitrosative Stress in the Pathogenesis of Diabetic Complications Prof. Csaba Szabo, Semmelweis University, Hungary and Uni- versity of Medicine and Dentistry of New Jersey, USA Is Endothelial Dysfunction a Therapeutic Target in Heart Fail- ure? Prof. Vincent Richard, Rouen University Hospital, France Nitrosative Stress and Circulatory Shock Prof. Salvatore Cuzzocrea, University of Messina, Italy Nitric Oxide/Nitrosative Stress Pathway in Brain Injury Dr Valerie Besson, University Paris Descartes, France Functional Selectivity and GPCRs Organisers: Dr Eamonn Kelly, University of Bristol, UK Prof. Graeme Henderson, University of Bristol, UK Speakers: Prof. Brian Koblika, Stanford University , USA Prof. Philip G Strange, University of Reading, UK 5 Prof. Michael Spedding, Institut de Recherche Servier, France Dr Chris P Bailey, University of Bath, UK Reducing QT Liability & Proarrhythmic Risk in Drug Discovery & Development Organiser: Dr Jean-Pierre Valentin, AstraZeneca, UK Speakers: Non-Clinical Strategies to address QT Liability and Proarrhythmic Risk Dr Chris Pollard, AstraZeneca, UK Value of Non-Clinical Repolarisation Assay Studies to Support Drug Discovery, Development, Regulatory Approval, and Life Cycle Management Dr Jean-Pierre Valentin, AstraZeneca, UK Through QT/QTc Study: A Review Three Years after Implementation Dr Borje Darpo, Consultant, Sweden Drug Induced QT Shortening – Is it an Issue? Dr Rashmi Shah, Medical and Healthcare products Regulatory Agency, UK Integrated Risk Assessment and Predictive Value to Humans of Non-Clinical Repolarisation Assays Dr Rob Wallis, Pfi zer, UK Calcium-Activated K+ Channels and Endothelial Cell Signalling – Therapeutic Target? Organisers: Prof. Ulf Simonsen, University of Aarhus, Denmark Dr Michel Félétou, Institut de Recherche Servier, France Speakers: K+ Channels and Release of EDHF Dr Gillian Edwards, University of Manchester, UK Role of K+ Channels in Restenosis and Angiogenesis Dr Ralf Köhler, Philipps-Universität, Germany K+ Channels and Release of Nitric Oxide Dr Edgaras Stankevicius, University of Aarhus, Denmark K+ Channels and Endothelial Dysfunction – Therapeutic Option? Dr Michel Félétou, Institut de Recherche Servier, France 6 The Histamine H3 and H4 Receptors: Drug Targets for the Anti-Histamines of the 21st Century Organisers: Dr Paul Chazot, University of Durham, UK Dr Ekaterini Tiligada, University of Athens, Greece Chairs: Prof. Steve Hill, University of Nottingham, UK Prof. Robin Ganellin, University College, UK Speakers: Histamine H3 Receptors in Psychiatric Diseases and Parkinson’s Disease Prof. Pertti Panula, University of Helsinki, Finland Histamine H3 Receptor Antagonists: From Target Identifi cation to Clinical Candidate Prof. Nicholas Carruthers, Johnson & Johnson, USA Histamine Receptors: From the Human Genome to New Therapeutic Options for Infl ammatory Disorders Prof. Rob Leurs, Vrije Universiteit Amsterdam, Netherlands The H4 Receptor and Potential Cancer Therapy Prof. Andras Falus, Semmelweis University, Hungary G12/13 Signalling of G Protein-Coupled Receptors: Mechanistic Insights and Therapeutic Impact Organiser: Dr Sandra Siehler, Novartis, Switzerland Speakers: Physiological Relevance of Galpha12 and Galpha13 in Various Tissues Dr Stefan Offermanns, University of Heidelberg, Germany Role of G12/13 Signalling in Cancer Invasion and Metastasis Dr Patrick J Casey, University of Durham, UK Regulation of RhoGEF Proteins by Galpha12/13-Coupled Receptors, and Disease-Related Context Dr Sandra Siehler, Novartis,